Establishment of a Biobank for the Evaluation of Rapid Diagnostic Solutions
1 other identifier
observational
800
1 country
10
Brief Summary
This multicenter prospective registry aims to establish a biobank of residual biological samples and associated clinical data from hospitalized patients. The registry will collect a wide range of specimens (serum, plasma, respiratory samples, urine, cerebrospinal fluid, biopsies) obtained during routine care, without any additional procedures. Data are pseudonymized and stored securely for up to 20 years. The biobank will be used to develop and evaluate rapid diagnostic tests (RDTs) for emerging infectious diseases and CBRN threats to improve epidemic preparedness and patient management.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2024
10 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 3, 2024
CompletedFirst Submitted
Initial submission to the registry
February 9, 2026
CompletedFirst Posted
Study publicly available on registry
February 17, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 1, 2026
February 17, 2026
January 1, 2026
2 years
February 9, 2026
February 9, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Number of residual clinical samples successfully collected, aliquoted, and stored with associated clinical and microbiological data
Creation of a collection of residual biological samples (serum, plasma, urine, respiratory samples, CSF, biopsies, etc.) and associated clinical and microbiological data obtained during routine care
36months (end of patient inclusion period)
Eligibility Criteria
Patients hospitalized in one of the participating study centers
You may qualify if:
- Adults (≥ 18 years old) hospitalized in one of the participating centers at Bicêtre or Paul Brousse hospitals, for whom residual biological samples are available as part of routine care in one or more participating hospital departments.
- Covered by, or entitled to, the French social security system (excluding State Medical Aid - AME).
- Patient or legal representative/trusted person informed about the registry and having provided written consent to participate.
You may not qualify if:
- Patients under judicial protection (guardianship or curatorship).
- Patients deprived of liberty by judicial or administrative decision.
- Patients not speaking French and not accompanied by a translator.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Assistance Publique - Hôpitaux de Parislead
- NG Biotechcollaborator
- Commissariat A L'energie Atomiquecollaborator
Study Sites (10)
CHU Bicêtre
Le Kremlin-Bicêtre, France
CHU Bicêtre
Le Kremlin-Bicêtre, France
CHU Bicêtre
Le Kremlin-Bicêtre, France
CHU Bicêtre
Le Kremlin-Bicêtre, France
CHU Bicêtre
Le Kremlin-Bicêtre, France
CHU Bicêtre
Le Kremlin-Bicêtre, France
CHU Bicêtre
Le Kremlin-Bicêtre, France
CHU Bicêtre
Le Kremlin-Bicêtre, France
CHU Bicêtre
Le Kremlin-Bicêtre, France
CHU Paul Brousse
Villejuif, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 9, 2026
First Posted
February 17, 2026
Study Start
June 3, 2024
Primary Completion (Estimated)
June 1, 2026
Study Completion (Estimated)
June 1, 2026
Last Updated
February 17, 2026
Record last verified: 2026-01